TY - JOUR
T1 - Gastro-oesophageal reflux disease
T2 - A pharmacist's perspective for 2020
AU - Schellack, N.
AU - Schellack, G.
AU - Meyer, J. C.
AU - Malan, L.
AU - Labuschagne, Q.
AU - Nxumalo, N.
AU - Kupa, K.
N1 - Publisher Copyright:
© 2020 Medpharm Publications. All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - Gastro-oesophageal reflux disease (GORD) produces symptoms that cause great irritation and discomfort to the patient. Pharmacotherapeutic management is directed at minimising these symptoms and reducing the causative factors, e.g. acid production, thereby providing the necessary relief. Currently available agents include simple antacids and acid suppression therapy, including histamine-2 receptor antagonists, proton-pump inhibitors, mucosal or cytoprotective agents and pro-motility agents. Deciding on appropriate therapy will be dependent upon the diagnosis, side-effects and cost-effectiveness of the treatment.
AB - Gastro-oesophageal reflux disease (GORD) produces symptoms that cause great irritation and discomfort to the patient. Pharmacotherapeutic management is directed at minimising these symptoms and reducing the causative factors, e.g. acid production, thereby providing the necessary relief. Currently available agents include simple antacids and acid suppression therapy, including histamine-2 receptor antagonists, proton-pump inhibitors, mucosal or cytoprotective agents and pro-motility agents. Deciding on appropriate therapy will be dependent upon the diagnosis, side-effects and cost-effectiveness of the treatment.
KW - Cytoprotective agents
KW - GORD
KW - Gastro-oesophageal reflux disease
KW - Histamine-2 receptor antagonists
KW - PPIs
KW - Proton-pump inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85099439669&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:85099439669
SN - 2221-5875
VL - 87
SP - 31
EP - 37
JO - SA Pharmaceutical Journal
JF - SA Pharmaceutical Journal
IS - 3
ER -